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PTENP1‑AS contributes 
to BRAF inhibitor resistance 
and is associated with adverse 
clinical outcome in stage III 
melanoma
Linda Vidarsdottir1, Alireza Azimi1, Ishani Das1, Ingibjorg Sigvaldadottir1, 
Aldwin Suryo Rahmanto2, Andreas Petri3, Sakari Kauppinen3, Christian Ingvar4, 
Göran Jönsson4, Håkan Olsson4, Marianne Frostvik Stolt1, Rainer Tuominen1, Olle Sangfelt2, 
Katja Pokrovskaja Tamm1, Johan Hansson1, Dan Grandér1, Suzanne Egyházi Brage1* & 
Per Johnsson2*
BRAF inhibitors (BRAFi) selectively target oncogenic  BRAFV600E/K and are effective in 80% of advanced 
cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug 
resistance limits their clinical efficacy. Better characterization of the underlying molecular processes 
is needed to further improve treatments. We previously demonstrated that transcription of PTEN is 
negatively regulated by the PTEN pseudogene antisense RNA, PTENP1‑AS, and here we investigated 
the impact of this transcript on clinical outcome and BRAFi resistance in melanoma. We observed 
that increased expression levels of PTENP1‑AS in BRAFi resistant cells associated with enrichment of 
EZH2 and H3K27me3 at the PTEN promoter, consequently reducing the expression levels of PTEN. 
Further, we showed that targeting of the PTENP1‑AS transcript sensitized resistant cells to BRAFi 
treatment and that high expression of PTENP1‑AS in stage III melanoma correlated with poor survival. 
Collectively, the data presented here show that PTENP1‑AS is a promising target for re-sensitizing 
cells to BRAFi and also a possible prognostic marker for clinical outcome in stage III melanoma.
Although cutaneous malignant melanoma is a molecularly diverse disease, approximately 50% carry activating 
mutations in the serine/threonine protein kinase BRAF. The majority of BRAF mutations are represented by a 
valine (V) to glutamic acid (E) or lysine (K) substitution at position 600  (BRAFV600E/K)1. These missense muta-
tions occur in the BRAF kinase domain, which results in constitutively active BRAF and subsequently activated 
MAPK signaling. Drug development efforts using a targeted approach have successfully led to the development 
of small inhibitory molecules (BRAFi, i.e. vemurafenib, dabrafenib, encorafenib), which specifically target the 
oncogenic  BRAFV600E/K. While 80% of patients with advanced melanoma carrying a  BRAFV600E/K mutation ini-
tially respond well to this treatment, resistance emerges within a median of 6–7 months of  treatment2. Although 
the time to emergence of resistance can be prolonged to 11 months when combined with MEK inhibitors, the 
5-year overall survival rate is only 34% for the combined  treatment3. In recent years there has been a growing 
understanding of the underlying molecular mechanisms involved in acquired BRAFi  resistance4,5 and activation 
of the PI3K/AKT pathway due to loss of PTEN has been found to contribute to this  process6. Therefore, better 
molecular understanding of the mechanisms that contribute to suppression of PTEN is desired and might help 
to identify novel approaches that could circumvent or delay the onset of resistance.
Approximately 14,000 pseudogenes have been identified in the human genome and roughly 900 of these have 
been reported to be transcribed into non-coding RNAs (ncRNAs)7. Molecular functions have been character-
ized for only a handful of these  pseudogenes8–11, for instance through microRNA (miRNA)  sponging10 and trans 
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acting antisense RNAs (asRNA)8. One of these, the PTEN pseudogene,  PTENP1 (also known as PTENpg1 and 
PTENΨ), is divergently transcribed into sense (PTENP1-S) and asRNA (PTENP1-AS) transcripts. While PTENP1-
S promote expression of PTEN by functioning as a miRNA sponge for PTEN related  miRNAs10, PTENP1-AS acts 
as a transcriptional suppressor by inducing epigenetic alterations at the PTEN  promoter8,12. Interestingly, loss of 
PTEN expression has been found during the development of resistance to  BRAFi6 and melanoma  metastasis13,14, 
but the involvement of PTENP1-AS remains unknown.
In this study, our aim was to characterize the impact of PTENP1-AS on clinical outcome in stage III melanoma 
and BRAFi treatment efficacy. We observe that the expression of PTENP1-AS is induced in BRAFi resistant 
sublines in relation to the parental sensitive cell line. This coincides with transcriptional suppression of PTEN, 
likely through the recruitment of EZH2 and subsequent formation of H3K27me3 at the PTEN promoter. Finally, 
we also demonstrate that expression of PTENP1-AS is increased in tumor samples from stage III melanoma 
patients with poor survival. In summary, our study provides insights into the involvement of PTENP1-AS in 
resistance to BRAFi treatment.
Results
Inverse correlation of PTEN and PTENP1‑AS in BRAFi resistant A375 sublines. Previous stud-
ies suggested downregulation of PTEN to be important upon the development of resistance to  BRAFi6,13. Based 
on these reports, we set out to investigate if PTENP1-AS was involved in this process through transcriptional 
suppression of PTEN. To do this, a series of BRAFi resistant melanoma sublines were obtained by culturing the 
BRAFi sensitive A375 cell line in increasing doses of BRAFi (A375PR1 (resistant to PLX4720), A375VR3 and 
A375VR4 (both resistant to vemurafenib))15. Compared to the parental A375 cells,  IC50 measurements for the 
A375PR1 and A375VR4 cell lines confirmed roughly six- to eight-fold increased tolerance to vemurafenib (Sup-
plementary Fig. S1), thus in agreement with a previous  study15. We next measured PTEN expression using West-
ern blot and qRTPCR and observed downregulation of PTEN at the protein (Fig. 1a, Supplementary Fig. S2a) as 
well as mRNA (Fig. 1b, Supplementary Fig. S2b) levels. Importantly, the negatively regulated downstream target 
of PTEN, p-AKT, showed a corresponding increase in phosphorylation compared to the parental A375 cell line 
(Fig. 1a, Supplementary Fig. S2a).
We next measured levels of PTENP1-encoded transcripts and identified a significant upregulation of PTENP1-
AS in all three resistant sublines (Fig. 1c, Supplementary Fig. S2c) and also a modest, although non-significant, 
induction of PTENP1-S (Fig. 1d, Supplementary Fig. S2d). Since previous studies had identified multiple isoforms 
of PTENP1-AS with distinct regulatory  functions8, we carefully investigated different isoforms in one of the sub-
lines (A375PR1). Multiple primer sets for the different variants of PTENP1-AS were assessed on semi-qRTPCR 
and revealed increased expression of all isoforms (Fig. 1e, Supplementary Fig. S3). Notably, unspliced RNA levels 
of PTENP1-AS was also found to be induced, indicating that PTENP1-AS is activated at the transcriptional level. 
Collectively, these initial observations motivated us to further elucidate the role of PTENP1-AS in resistance to 
BRAFi.
PTENP1‑AS suppresses PTEN in BRAFi resistant cells through chromatin remodeling. To 
investigate the molecular interplay between PTENP1-AS and PTEN in greater detail, we focused, from here, 
on the A375PR1 subline. We designed a gapmer antisense oligonucleotide (ASO) (Fig. 2a,b) and also an siRNA 
targeting the PTENP1-AS transcript (Fig. 2c,d) and confirmed knockdown in A375 as well as in A375PR1 cells 
using qRTPCR. Intriguingly, knockdown of PTENP1-AS only induced the expression of PTEN in the A375PR1 
cells, while PTEN remained unaffected in the vemurafenib sensitive A375 cells (Fig.  2a–d), suggesting that 
PTENP1-AS is predominantly active in the resistant subline. In contrast, no effect on PTENP1-S expression 
levels was observed in either cell line upon knockdown of PTENP1-AS (Supplementary Fig. S4).
We next asked if suppression of PTEN in the A375R1 subline was due to epigenetic changes at the PTEN 
promoter since high promoter methylation has been commonly observed in melanoma and is associated with 
poor clinical  outcome16. PTEN promoter CpG methylation was assessed by the methyl-cytosine-specific McrBc 
restriction enzyme. qRTPCR showed increased enzymatic cleavage in the A375PR1 subline, compared to the 
parental A375 cells (Fig. 3a), thus suggesting increased PTEN promoter CpG methylation in the resistant subline. 
Since we have previously reported PTENP1-AS to modulate transcription of PTEN through the recruitment of 
EZH2 and  DNMT3A8,12, we next measured levels of EZH2 and H3K27me3 at the PTEN promoter. Chromatin 
immunoprecipitation (ChIP) followed by qRTPCR revealed increased levels of EZH2 and H3K27me3 at the 
PTEN promoter in the A375PR1 subline (Fig. 3b,c), while the baseline expression levels of DNMT3A and EZH2 
were similar in the resistant and parental cell lines as measured by qRTPCR (Fig. 3d,e). To further interrogate 
their role in suppression of PTEN, EZH2 and DNMT3A were depleted using siRNAs. Although individual 
siRNA-mediated knockdown only resulted in a modest induction of PTEN (Fig. 3f,g, Supplementary Fig. S5a,b), 
simultaneous knockdown generated over a twofold induction of PTEN in the A375PR1 cells, in contrast to the 
parental A375 cells, where the expression of PTEN was largely unchanged (Fig. 3h, Supplementary Fig. S5c,d). 
Altogether, these data suggest that suppression of PTEN is mediated by PTENP1-AS likely through the recruit-
ment of EZH2 by a mechanism that may be exclusively active in the vemurafenib resistant cells.
C/EBPB is a transcriptional regulator of PTENP1‑AS. To explore mechanisms underlying transcrip-
tional induction of PTENP1-AS (Fig. 1c), we took advantage of FANTOM5 CAGE data and ChIP-sequencing 
data from the UCSC Genome Browser and identified a binding site for the transcription factor (TF) C/EBPB 
close to the PTENP1-AS transcriptional start site (TSS) (Fig. 4a). Comparing A375PR1 to A375 cells, revealed 
an increased RNA expression of C/EBPB by qRTPCR (Fig. 4b), and ChIP further identified increased levels of 
C/EBPB at the PTENP1-AS promoter (Fig. 4c) in A375PR1 cells. Targeting C/EBPB with dsiRNA reduced the 
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expression of unspliced PTENP1-AS in the A375PR1 cells (Fig. 4d), while no significant change was identified 
for PTENP1-S (Supplementary Fig. S6), thus suggesting that C/EBPB functions as a transcriptional activator of 
PTENP1-AS.
PTENP1‑AS is a clinically relevant target and a prognostic marker in melanoma. We next 
explored if the resistant A375PR1 cells could be sensitized to BRAFi by targeting the PTENP1-AS transcript. 
Gapmer ASO-mediated suppression did not have an effect on the basal levels of cell death but sensitized resistant 
cells to treatment with 10 μM of vemurafenib (Fig. 5a), as measured by annexin V and propidium iodide stain-
ing. To further validate this effect, we performed a colony formation assay and also included a second resistant 
subline, A375VR4. While gapmer ASO-mediated knockdown of PTENP1-AS had minor effect on colony for-
mation in parental A375, both resistant sublines were clearly sensitized to vemurafenib, in particular at lower 
concentrations (1 μM) (Fig. 5b, Supplementary Fig. S7).
We finally set out to investigate the relevance of PTENP1-AS in tumors from melanoma patients. The expres-
sion levels of PTEN and PTENP1-AS were first assessed in melanoma samples from the TCGA (The Cancer 
Genome Atlas program) where although weak but a significant negative correlation was observed (r = − 0.20, 
p = 1.6e−3, Fig. 5c). The expression of PTENP1-AS was next determined in lymph node metastases from a cohort 
of 20 stage III melanoma patients. The samples were initially chosen to include two groups of patients, with either 
long (≥ 60 months) or short (≤ 13 months) overall  survival17, and the expression of PTENP1-AS was determined 


















































































































































Figure 1.  Expression levels of PTEN and PTENP1-lncRNAs in BRAFi sensitive and resistant cell lines. (a) 
Western blot analysis presenting the expression of PTEN, total AKT and p-AKT in A375 and the BRAFi 
resistant sublines. (b–d) qRTPCR analysis of (b) PTEN, (c) PTENP1-AS and (d) PTENP1-S in A375 and the 
BRAFi resistant A375PR1 subline (n = 3, p-values represent a two-tailed student’s t-test). (e) Semi-qRTPCR 
assay showing different isoforms of the PTENP1-AS transcripts with a scheme showing primer binding sites.
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had poor survival, while low expression of PTENP1-AS seemed to be indicative of prolonged survival, although 
not reaching significance (p = 0.06) (Fig. 5d). This motivated us to evaluate the expression of PTENP1-AS in an 
independent second cohort of stage III melanoma metastasis samples. Lymph node metastases from 29 stage 
III melanoma patients were analyzed for the expression of PTENP1-AS. The patient samples from the second 
cohort were divided in high (n = 12) or low (n = 17) expression of PTENP1-AS, as determined by qRTPCR, 
and a survival plot was generated (Fig. 5e). A significant difference in overall survival was observed between 
patients with high and low expression of PTENP1-AS. In summary, the expression of PTENP1-AS appears to 
be a promising prognostic marker for clinical outcome, where increased expression of PTENP1-AS correlates 
with poor overall survival.
Discussion
The data presented in this study suggest a role for PTENP1-AS in the development of resistance to BRAFi. On 
the basis of our data, we suggest that expression of PTENP1-AS is induced by the TF C/EBPB in BRAFi resistant 
melanoma cell lines, which results in transcriptional suppression of PTEN through the recruitment of EZH2 
with subsequent formation of H3K27me3 (Fig. 3b,c) and DNA methylation of the PTEN promoter (Fig. 3a). 
















































































































Figure 2.  Effect on PTEN expression upon knockdown of PTENP1-AS. (a,b) qRTPCR measuring the 
expression levels of PTENP1-AS and PTEN in (a) A375PR1 or (b) A375 cells upon knockdown of PTENP1-AS 
using gapmer ASO. (c,d) qRTPCR measuring the expression levels of PTENP1-AS and PTEN in (c) A375PR1 or 




Scientific Reports |        (2021) 11:11023  | https://doi.org/10.1038/s41598-021-89389-9
www.nature.com/scientificreports/
where high expression of PTENP1-AS in first regional lymph node metastases correlates with poor overall sur-
vival. In summary, our findings bring important information about molecular functions of PTENP1-AS upon 
development of BRAFi resistance and better understanding of this pathway could reveal novel approaches to 
re-sensitize drug resistant cells.
Our data are consistent with our previous findings demonstrating that PTENP1-AS is a negative regulator 
of PTEN through chromatin remodeling of the PTEN  promoter8. Targeting the PTENP1-AS transcript using 
gapmer ASOs and siRNAs generate a moderate induction of PTEN exclusively in the resistant subline (Fig. 2), 
thus demonstrating that the PTENP1-AS transcript does not act as an on/off switch for PTEN expression, but 
rather causes subtle variations of transcription in a phenotype-dependent  manner8. These variations of PTEN 
expression are within physiological relevant levels where a modest decrease of 20% have been shown to increase 
cancer  susceptibility18.
Our data is also consistent with previous RNA-sequencing studies showing induction of C/EBPB in BRAFi 
resistant  cells19. However, these previous studies did not report PTEN or PTENP1-AS as candidate genes involved 








































































































































































































































































































































Figure 3.  Characterization of the PTEN promoter in A375 and A375PR1 cell lines. (a) qRTPCR measuring 
PTEN promoter CpG methylation, as determined by the remaining (unmethylated) DNA upon treatment 
with the methyl-cytosine-specific restriction enzyme McrBc (n = 3). (b–c) ChIP followed by qRTPCR analysis 
measuring the levels of (b) EZH2 and (c) H3K27me3 at the PTEN promoter in A375 and A375PR1 cell lines 
(n = 3). (d–e) qRTPCR measuring baseline expression levels of (d) DNMT3A and (e) EZH2 in A375 and 
A375PR1 cell lines (n = 3). (f–g) qRTPCR measuring the expression levels of PTEN following siRNA induced 
knockdown of (f) DNMT3A and (g) EZH2 in A375 and A375PR1 cell lines (n > 3). (h) qRTPCR measuring the 
expression levels of PTEN following simultaneous siRNA-induced knockdown of EZH2 and DNMT3A in A375 
and A375PR1 cell lines (n = 3). (a–h; p-values represent a two-tailed student’s t-test).
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on our study, both PTEN and PTEN1-AS are likely to be excluded from such an analysis when these thresholds 
are applied.
Several PTENP1-encoded lncRNAs with opposing functions have been described. While the miRNA sponge 
model suggests concordant expression of PTEN and PTENP1-S10, we have not observed this phenomenon in the 
present study, despite a modest induction of PTENP1-S (Fig. 1d, Supplementary Fig. S2d). Instead, the PTENP1-
AS transcript appears to be the dominant regulator of PTEN expression under these conditions. However, this 
does not exclude that miRNA sponging could take place as well. A regulatory mechanism, where translation as 
well as transcription of PTEN is regulated through lncRNAs encoded by the PTENP1 locus is still a plausible 
scenario. Subtle variations of PTEN expression have previously been reported to be associated with cancer 
























































































































Figure 4.  Transcriptional regulation of PTENP1-AS by C/EBPB. (a) A scheme showing binding of C/EBPB at 
the PTENP1 locus (data retrieved from the Zenbu FANTOM5 CAGE and the UCSC genome browser) and the 
predicted DNA binding site for C/EBPB (R is an A/G, Y is C/T). (b) qRTPCR measuring the expression levels 
of C/EBPB (n > 3). (c) ChIP followed by qRTPCR analysis measuring the levels of C/EBPB at the PTENP1-AS 
promoter (n = 3). (d) qRTPCR measuring expression levels of C/EBPB and unspliced PTENP1-AS in A375PR1 
cells upon siRNA-induced knockdown of C/EBPB (n = 3).
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Figure 5.  Manipulation of PTENP1-AS in BRAFi resistant sublines and evaluation of PTENP1-AS in metastatic 
melanoma samples. (a) Cell-death analysis by annexin V and propidium iodide staining upon knockdown of 
PTENP1-AS and vemurafenib treatment (n = 6). (b) Colony formation assays for A375, A375PR1 and A375VR4 
cell lines measuring relative absorbance of crystal violet solution stained colonies upon gapmer ASO-induced 
knockdown of PTENP1-AS co-treated with various concentrations of vemurafenib. (c) Expression data (TCGA) for 
PTEN and PTENP1-AS from melanoma samples. (d) qRTPCR measuring expression levels of PTENP1-AS in a set 
of 20 first regional lymph node metastases from stage III melanoma patients. Based on clinical follow up data, the 
patients were categorized as long- or short-term survivors, > 60 months or ≤ 13 months, respectively. (e) Kaplan–
Meier plot showing overall survival for patients with high (n = 12) or low (n = 17) expression levels of PTENP1-AS. 
Expression levels of PTENP1-AS was measured in first regional lymph node metastases from an independent set of 
29 stage III melanoma patients using qRTPCR. The p-value represents a log-rank test.
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carcinogenesis. It is therefore likely that PTEN is regulated at several different levels. Deletions of PTENP1 have 
been reported in melanoma cell lines and tissues, supporting that suppression of PTEN also occurs at the post-
transcriptional level through miRNA-mediated  regulation20. It is also likely that tissue and cell type specific 
expression levels of i.e. DNMT3A, EZH2 and miRNAs dictate the regulatory outcome of PTENP1-encoded 
lncRNAs, and PTENP1-S may also be involved in sponging of miRNAs related to other mRNAs beyond PTEN21.
Notably, this study also shows that the suppression of PTEN in BRAFi resistant cells may be reversible through 
targeting of EZH2, DNMT3A as well as PTENP1-AS. The individual knockdown of EZH2 or DNMT3A did not 
re-activate the expression of PTEN to the same extent as a simultaneous knockdown of these proteins (Fig. 3f–h). 
We speculate that this is due to incomplete knockdown of DNMT3A and EZH2 where some active protein 
complexes may still be present under these circumstances (Supplementary Fig. S5). An interaction between 
EZH2 and DNMT3A have been  demonstrated22 and the combined knockdown of EZH2 and DNMT3A may 
in this case be more efficient in reducing these protein complexes. Importantly, the induction of PTEN is more 
prominent in the A375PR1 cells than in the parental cells, indicative of a therapeutic window for re-activation 
of PTEN in BRAFi resistant melanoma cells. In support of this, we show that manipulation of the PTENP1-AS 
pathway re-sensitized the A375PR1 and A375VR4 resistant cells to treatment with vemurafenib (Fig. 5a,b and 
Supplementary Fig. S7).
We evaluated the expression of PTENP1-AS in regional lymph node metastases of stage III melanoma and 
found that high expression correlated with poor survival (Fig. 5d,e). This indicates that PTENP1-AS may be 
involved in melanoma tumor progression and is not only important during the development of resistance to 
BRAFi. Also, development of a particular type of resistance to vemurafenib may depend on the pre-existing 
factors/pathways in the tumors. High expression of PTENP1-AS could, for example, indicate that the tumor 
is less likely to respond to treatment and loss of PTEN expression has previously been linked to  metastasis13. 
Therefore, one may speculate that PTENP1-AS is involved in such inactivation and consequently enhance ini-
tiation of distant metastasis. Additional studies will be required to better understand the functional role and 
importance of PTENP1-AS in melanoma progression and drug resistance i.e. by taking patient samples pre- and 
post- treatment with BRAFi.
In summary, we have identified PTENP1-AS to be involved both in melanoma tumor progression and in 
development of resistance to vemurafenib. The data presented here show that PTENP1-AS is not only a promising 
target for re-activation of PTEN, but also a possible prognostic marker for clinical outcome in stage III melanoma.
Materials and methods
Cell cultures. A375 cells were purchased from ATCC (CRL-1619). A375, A375PR1, A375VR3 and A375VR4 
cell lines were cultured in 5%  CO2 at 37 °C in MEM supplemented with 10% heat-inactivated FBS, 2 mM glu-
tamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 50 μg/ml of streptomycin and 50 μg/ml 
of penicillin. As previously  described15, resistant A375 cell lines had been generated by repeated exposures to 
increasing concentrations of vemurafenib (A375VR3 and A375VR4) or its analog PLX4720 (A375PR1).
RNA extraction and cDNA. RNA was extracted using the RNA NucleoSpin II kit (Macherey–Nagel) and 
treated with DNase (Ambion Turbo DNA-free, Life Technologies). DNase treated RNA (~ 500 ng) was used for 
the generation of cDNAs using M-MLV (Life Technologies) and a mixture of oligo(dT)15 with nanomers.
Semi-qRTPCR. PCR was performed by using the KAPA2G FAST mix (Kapa Biosystems) according to the 
manufacturer’s recommendations and by using the corresponding oligos in Supplementary Table 1.
qRTPCR. qRTPCR was performed by using the KAPA 2G SYBR Green (Kapa Biosystems) on the Applied 
Biosystems 7900HT or the BioRad CFX96 Touch platform with the following cycling conditions: 95  °C for 
3 min, 95 °C for 3 s, 60 °C for 30 s. The corresponding oligos for each gene is specified in Supplementary Table 1.
siRNAs and gapmers. siRNAs and gapmer antisense oligonucleotides, ASOs, were ordered from the 
respective manufacturers (Supplementary Table 1) and transfected using lipofectamine 2000 (Life Technologies) 
according to the manufacturer’s recommendations. A final concentration of 10–40 nM was used for the siRNAs 
and gapmer ASOs and PLUS Reagent (Life Technologies), which was added for transfections of gapmers ASOs.
Protein analysis. Samples were lysed in 50 mM Tris–HCl, pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 
1% glycerol, 100 μM vanadate, protease inhibitor cocktail and PhosSTOP (Roche Diagnostics GmbH). Lysates 
were subjected to SDS-PAGE using 4–12% acrylamide gels (Life Technologies) and transferred to PVDF mem-
branes using the iBlot system (Life Technologies). The proteins were detected by western blot analysis by using 
an enhanced chemiluminescence system (Western Lightning–ECL, PerkinElmer). Antibodies used were specific 
for PTEN (Cell Signaling, cat. no. 9552, 1:1000), AKT (Cell Signaling, cat. no. 9272, 1:1000), phospho-AKT (Cell 
signaling, cat. no. 4060S, 1:1000) and β-actin (Sigma-Aldrich, cat. no. A5441, 1:5000). Membranes were first 
incubated for p-AKT followed by reprobing the same membranes for total AKT and PTEN.
ChIP of EZH2, H3K27me3 and C/EBPB. ChIP assays were performed as previously  described8. Briefly, 
the ChIP assay Kit (Upstate/Millipore) was used by crosslinking the cells in 1% formaldehyde for 10  min, 
quenched in 0.125 M Glycine for 5 min and lysed according to the manufacturer’s recommendations. The sam-
ples/nuclei were sonicated with a Bioruptor Sonicator (Diagenode) at 30 s ON, 30 s OFF (setting = high) for a 
total of 18 cycles. The water was replaced with ice-cold water after every sixth cycle. The samples were diluted 
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1:10 in ChIP dilution buffer, pre-cleared and incubated overnight with the appropriate antibody. Salmon sperm 
DNA/Protein A-agarose (Upstate/Millipore) was used to pull down the antibody. The DNA was eluted in elu-
tion buffer (1% SDS, 100  mM  NaHCO3), followed by reverse cross-linking at 65  °C overnight. The samples 
were RNase-A and protease-K treated and finally eluted using the Qiagen PCR purification kit (Qiagen). The 
following antibodies were used (4 μg/sample): H3K27me3 (Upstate/Millipore, cat. no. 17-622), EZH2 (Upstate/
Millipore, cat. no. 07-689) and C/EBPB (Santa Cruz Biotechnology cat. no. sc-150).
Assessment of methylated DNA. The methyl-cytosine-specific McrBc restriction enzyme McrBc (New 
England Biolabs) was used to cleave methylated DNA. Briefly, 200 ng DNA was digested with McrBc at 37 °C 
overnight and heat inactivated the next day at 65 °C for 1 h. Samples were run on a qPCR machine and stand-
ardized to uncut input. Delta CT values were converted to fold-change values and the ratio between A375PR1/
A375 was calculated.
PI-annexin V staining. The cells were harvested, washed twice in PBS and resuspended in 100 μL annexin 
V incubation buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 5 mM  CaCl2) containing 1% annexin V 
FLOUS (Roche Molecular Biochemicals) and 500 μg/μL PI stain. The samples were incubated for 15 min at room 
temperature followed by adding 400 μL of ice-cold annexin V incubation buffer and subsequently analyzed on 
a cytometry machine.
IC50 measurements. 4,000 cells per well were plated in 96 well plate format. The following day, cells were 
treated with the BRAFi vemurafenib (Selleckchem) at the indicated doses and further incubated for 72 h. The cell 
viability was then analyzed by MTS assay (Promega, Madison, WI, USA) according to manufacturer’s protocol 
followed by absorbance read at 490 nM using Tecan Spark 10 M plate reader (Tecan Trading AG, Switzerland). 
IC50 was analyzed using Graphpad Prism 8.0.
Colony formation assay. 1000 cells per well were plated in 6 well plates and transfected 24  h later by 
using lipofectamine RNAiMax (Life Technologies), at a final concentration of 20 nM of gapmer ASO (Control 
or PTENP1-AS). Vemurafib treatment (or DMSO control) was initiated the day after transfection, cells were let 
grown for another 8–10 days before being fixed in 4% buffered formaldehyde and stained with 0.05% crystal 
violet. To estimate number of colonies, crystal violet staining was dissolved in 100% methanol, diluted to 1:10 in 
PBS and absorbance was measured at 540 nM using a Tecan Spark 10 M plate reader.
TCGA analysis. Gene expression profiles from GDC-TCGA (Genomic Data Commons—Cancer Genome 
Atlas) were utilized to correlate the expression of PTENP1-AS and PTEN in skin cutaneous melanoma (SKCM). 
We used the Xena browser (https:// xenab rowser. net) to extract the RNA expression data for each gene, excluded 
samples with no expression of PTENP1-AS and PTEN, and correlated their expression using Spearman correla-
tion (n = 251).
Patient samples. First regional lymph node metastases from stage III melanoma patients that had not 
received any systemic treatment were collected. The RNA was extracted using the Qiagen RNeasy mini kit (Qia-
gen). The RNA was DNase treated on column according to the manufacturer’s recommendations. The expression 
of PTENP1-AS was analyzed using qRTPCR and standardized to Beta-actin (dCt) by using the corresponding 
oligos in Supplementary Table 1. ddCt was calculated by using the mean Ct value of all samples. High expression 
of PTENP1-AS (Fig. 5e) was defined as Ct < 30.
Statistics. Two tailed Student’s T-test was used to determine statistical significance. Error bars represent the 
standard error of the mean. Statistical significance of the melanoma patient samples in Fig. 5e is evaluated using 
log-rank test. Throughout the paper, *P < 0.05; **P < 0.01; ***P < 0.005.
Ethical approval and consent to participate. This study has been approved by the Research Ethics 
Committee of Karolinska Institutet (Dnr: 2006/1373-31/3) and the Regional Ethics Committee in Lund (Dnr 
2013/101). All involved individuals have provided informed consent to be included in the study. All the study 
procedures were carried out in accordance with relevant guidelines.
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